“…Thus, previous MRS studies showed that a decreased Glx level can be observed in neurodegenerative conditions, such as aging (Goryawala et al, 2016;Grachev et al, 2001), mild cognitive impairment and Alzheimer's disease (Antuono et al, 2001;Huang et al, 2016;Riese et al, 2015), in several GM regions including mPFC and PCC, which implies neuronal dysfunction and loss in these GM regions. Consistently, cognitive performance or cognitive symptoms have been reported to positively correlate with Glx levels in elderly people (Zahr et al, 2008) and patients with mild cognitive impairment (Nikolova et al, 2017) and Alzheimer's disease (Walecki et al, 2011). Then, an increased cortical MD, which has been observed in aging and the above-mentioned diseases (Lin et al, 2016;Ni et al, 2010;Ray et al, 2006;Weston et al, 2015), may reflect the decline in the magnitude of microstructural organization in the GM associated with aging and age-related diseases, i.e.…”